Novel Anti-obesity Medication – a Promise for Overweight Patients1
Obesity has long been a global health challenge while the availability of pharmacological options remains limited. A recent investigation has found that obese adults may achieve weight loss with once-weekly semaglutide as an adjunct to lifestyle intervention. In a double-blind trial, 1,961 adults with a body mass index of ≥30 and also without diabetes, were randomly assigned to receive 68 weeks of once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo, concomitantly with lifestyle intervention. The administration of semaglutide plus lifestyle intervention was associated with a sustained reduction in body weight. The mean percent change of body weight from baseline to week 68 was −14.9% and −2.4% in the semaglutide and placebo groups respectively. The findings appear to be a potential in weight management for obese adults.
References
1. Wilding JPH, et al. N Engl J Med. 2021;384:989.
